Ikarian Capital, LLC Reports New 6.3% Passive Stake in Lipocine Inc. (LPCN)

On May 15, 2026, Ikarian Capital, LLC filed a Schedule 13G regarding its holdings in Lipocine Inc. (LPCN). The filing reveals that as of March 31, 2026, Ikarian Capital and its managing member, Neil Shahrestani, beneficially own 508,556 shares of common stock, representing a 6.3% ownership stake in the company. This position marks a new significant holding for the firm, as the previous reported ownership was 0%. The shares are held across the Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts. Ikarian Capital serves as the investment manager and sub-adviser for these entities, granting it shared voting and dispositive power over the securities. The filing was made under Rule 13d-1(b), indicating that the shares were acquired in the ordinary course of business and not with the intent to influence or change control of the issuer. The ownership percentage is based on 8,025,115 shares of common stock outstanding as of April 6, 2026.